Roman Butler Fullerton & Co’s BioMarin Pharmaceuticals BMRN Stock Holding History

Roman Butler Fullerton & Co’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-10,841	Closed	-$1.04M	–	188
2023 Q1	$1.04M	Sell	10,841 -3,796	-26%	-$394K	0.52%	60
2022 Q4	$1.64M	Buy	14,637 +2,256	+18%	+$212K	0.85%	28
2022 Q3	$1.09M	Buy	12,381 +2,019	+19%	+$180K	0.69%	40
2022 Q2	$902K	Buy	+10,362	New	+$825K	0.5%	63
2020 Q3	–	Sell	-7,585	Closed	-$936K	–	154
2020 Q2	$936K	Sell	7,585 -793	-9%	-$78.8K	0.67%	53
2020 Q1	$708K	Buy	+8,378	New	+$722K	0.62%	57

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Roman Butler Fullerton & Co's BMRN Position: Q2 2023 in Review

Roman Butler Fullerton & Co sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2023, closing a stake of 10,841 shares — an estimated $1.04M sold.

Roman Butler Fullerton & Co first reported a position in BMRN in Q1 2020 and held it in 6 quarters. The position peaked at $1.64M in Q4 2022. 558 funds tracked by Wall St. Rank hold BMRN as of Q2 2023.

Roman Butler Fullerton & Co reported no remaining BioMarin Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Roman Butler Fullerton & Co sold 10,841 BioMarin Pharmaceuticals shares in Q2 2023, an estimated $1.04M.
Roman Butler Fullerton & Co first reported a position in BioMarin Pharmaceuticals in Q1 2020 and held it in 6 quarters.
Roman Butler Fullerton & Co's BioMarin Pharmaceuticals position peaked at $1.64M in Q4 2022.
558 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2023.

Based on Roman Butler Fullerton & Co's 13F filing for Q2 2023, filed 25 Jul 2023.